Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a potent endothelial cell mitogen which mediates its effects by binding to tyrosine kinase receptors. We have characterized the VEGF-activated intracellular signal transduction pathway in bovine aortic endothelial cells and correlated this to its mitogenic effects. VEGF induced concentration- and time-dependent increases in protein kinase C (PKC) activation with a maximum of 2.2-fold above the basal level at 5 x 10(-10) M within 10 min as measured both by in situ and translocation assays. Immunoblotting analysis of PKC isoforms in cytosolic and membrane fractions indicated that after VEGF stimulation the content of Ca(2+)-sensitive PKC isoforms (alpha and betaII) was increased in the membrane fractions, whereas no changes were observed for PKC isoforms delta and epsilon. The stimulation of PKC activity by VEGF was preceded by the activation of phospholipase Cgamma (PLCgamma). This was demonstrated by parallel increases in PLCgamma tyrosine phosphorylation, [3H]inositol phosphate production, and [3H]arachidonic acid-labeled diacylglycerol formation in bovine aortic endothelial cells. In addition, VEGF increased phosphatidylinositol 3-kinase activity 2.1-fold which was inhibited by wortmannin, a phosphatidylinositol 3-kinase inhibitor, without decreasing the VEGF-induced increase in PKC activity or endothelial cell growth. Interestingly, genistein, a tyrosine kinase inhibitor, and GFX or H-7, PKC inhibitors, abolished both VEGF-induced PKC activation and endothelial cell proliferation. VEGF's mitogenic effect was inhibited by a PKC isoform beta-selective inhibitor, LY333531, in a concentration-dependent manner. In contrast, antisense PKC-alpha oligonucleotides enhanced VEGF-stimulated cell growth with a simultaneous decrease of 70% in PKC-alpha protein content. Thus, VEGF appears to mediate its mitogenic effects partly through the activation of the PLCgamma and PKC pathway, involving predominately PKC-beta isoform activation in endothelial cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, within the TME, PKC beta, another PKC isoform, is a well‐documented effector of the VEGF signaling that promotes angiogenesis and is required for invasiveness in certain tumors, such as pancreatic tumors [122, 123, 124].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [122]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302 · cited 2×
“and assayed by the method of Bradford (19).”
MethodInfluentialA RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751 · cited 1×
“The cells were scraped and total lipids were extracted with chloroform according to the methods of Bligh and Dyer (22).”
MethodVascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 2×
“VEGF was independently isolated as both an endothelial cell growth factor (1) and as a vasopermeability factor (3).”
BackgroundVascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Intracellular Signaling by Hydrolysis of Phospholipids and Activation of Protein Kinase C
Nishizuka, Y. (1992) · Science · doi:10.1126/science.1411571 · Cited by 4,472 · cited 4×
“In contrast, PKC isoforms e and d, which lack Ca(21) binding sites, are only responsive to DAG and did not translocate adequately for our antibodies to detect (25).”
BackgroundMethodInfluentialAiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793 · cited 2×
“Physiologically, elevated levels of VEGF have been associated with tumor angiogenesis (7) and hypoxia-induced proliferative ocular disorders such as diabetic proliferative retinopathy and retinal vein occlusion (8, 9).”
BackgroundSelf-citationGenistein, a specific inhibitor of tyrosine-specific protein kinases.
Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., & Fukami, Y. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45614-1 · Cited by 3,724 · cited 1×
“The addition of genistein (40 mm), a tyrosine kinase inhibitor (27), significantly reduced the VEGF-induced tyrosine phosphorylation of PLCg.”
BackgroundOncogenes and signal transduction
Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R., & Soltoff, S. (1991) · Cell · doi:10.1016/0092-8674(91)90639-g · Cited by 2,694 · cited 2×
“Since PI 3-kinase has been shown to be associated with several different tyrosine kinase receptors (29), and VEGF has been reported to increase PI 3-kinase tyrosine phosphorylation (12, 13), we determined whether PI 3-kinase activity could also be activated by VEGF.”
BackgroundThe bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C
Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., & Loriolle, F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98476-0 · Cited by 2,456
Plate, K. H., Breier, G., Weich, H. A., & Risau, W. (1992) · Nature · doi:10.1038/359845a0 · Cited by 2,275 · cited 1×
“Physiologically, elevated levels of VEGF have been associated with tumor angiogenesis (7) and hypoxia-induced proliferative ocular disorders such as diabetic proliferative retinopathy and retinal vein occlusion (8, 9).”
Background
Cited by
Gerber, H.-P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30336 · Cited by 1,981
Signal transduction by vascular endothelial growth factor receptors
Koch, S., Tugues, S., Li, X., Gualandi, L., & Claesson-Welsh, L. (2011) · Biochemical Journal · doi:10.1042/bj20110301 · Cited by 1,635
“The PKC isoforms PKCb (Xia et al. 1996; Takahashi et al. 1999), as well as PKCa and PKCz have been shown to regulate VEGFmediated proliferation (Wellner et al. 1999).”
BackgroundMechanisms and regulation of endothelial VEGF receptor signalling
Simons, M., Gordon, E., & Claesson-Welsh, L. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.87 · Cited by 1,498
Papapetropoulos, A., García-Cardeña, G., Madri, J. A., & Sessa, W. C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119868 · Cited by 1,191
“Stimulation of bovine aortic endothelial cells with VEGF has been shown to cause phosphorylation and activation of the phosphoinositide- 3 kinase (PI-3K) (34, 35).”
BackgroundInfluentialHolmes, K., Roberts, O. L., Thomas, A. M., & Cross, M. J. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.05.013 · Cited by 1,020
Molecular Understanding of Hyperglycemia's Adverse Effects for Diabetic Complications
Sheetz, M. J. (2002) · JAMA · doi:10.1001/jama.288.20.2579 · Cited by 1,002
Self-citationActivation of Protein Kinase C Isoforms and Its Impact on Diabetic Complications
Geraldes, P., & King, G. L. (2010) · Circulation Research · doi:10.1161/circresaha.110.217117 · Cited by 985
Self-citationProtein kinase C and other diacylglycerol effectors in cancer
Griner, E. M., & Kazanietz, M. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2110 · Cited by 978
“Several PKC isoforms, including PKCα, β and e, are activated in response to VEGF receptor activation, and PKC has been implicated as an important mediator of VEGF-induced proliferation of endothelial cell”
BackgroundVascular endothelial growth factors and angiogenesis in eye disease
Witmer, A. (2003) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(02)00043-5 · Cited by 927
R�sen, P., Nawroth, P. P., King, G., M�ller, W., Tritschler, H.-J., & Packer, L. (2001) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.196 · Cited by 887
“Antioxidants as well as inhibition of PKC activity by selective inhibitors decrease cell proliferation and permeability in diabetic retinopathy, in aortic smooth muscle and mesangial cells and supports the close relationship between oxidative stress and PKC activation [165,173,230,231,242,243].”
BackgroundSelf-citationRegulation of angiogenesis via vascular endothelial growth factor receptors.
Veikkola, T., Karkkainen, M. J., Claesson, L., & Alitalo, K. K. (2000) · PubMed · Cited by 876
Diabetic Retinopathy and Diabetic Macular Edema
Ciulla, T. A., Amador, A. G., & Zinman, B. (2003) · Diabetes Care · doi:10.2337/diacare.26.9.2653 · Cited by 836
“The role of VEGF in retinal neovascularization has also prompted the development of VEGF-specific inhibitors such as antibodies to VEGF (134).”
BackgroundInfluentialKim, I., Moon, S.-O., Hoon Kim, S., Jin Kim, H., Soon Koh, Y., & Young Koh, G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009705200 · Cited by 760
Oxidative Stress and Diabetic Retinopathy
Kowluru, R. A., & Chan, P.-S. (2007) · Journal of Diabetes Research · doi:10.1155/2007/43603 · Cited by 746
“Activated PKC can bring about a variety of changes characteristic of diabetic retinopathy that include increasing vessel permeability, blood flow, alteration of hormone and growth factor receptor recycling, stimulation of neovascularization, endothelial proliferation and apoptosis, and regulating the action of several…”
BackgroundVEGFs and receptors involved in angiogenesis versus lymphangiogenesis
Lohela, M., Bry, M., Tammela, T., & Alitalo, K. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.012 · Cited by 738
Klaassen, I., Van Noorden, C. J. F., & Schlingemann, R. O. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.02.001 · Cited by 722
“signaling pathways that are increased by hyperglycemia (Aiello, 2002) and also acts as a downstream mediator of VEGF (Xia et al., 1996).”
BackgroundThe Role of Inflammatory Cytokines in Diabetes and Its Complications
King, G. L. (2008) · Journal of Periodontology · doi:10.1902/jop.2008.080246 · Cited by 679
Self-citationZachary, I. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00268-6 · Cited by 662
Fong, D. S., Aiello, L. P., Ferris, F. L., & Klein, R. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2540 · Cited by 640
Self-citationKuboki, K., Jiang, Z. Y., Takahara, N., Ha, S. W., Igarashi, M., Yamauchi, T., Feener, E. P., Herbert, T. P., Rhodes, C. J., & King, G. L. (2000) · Circulation · doi:10.1161/01.cir.101.6.676 · Cited by 639
Self-citationDifferential Roles of Vascular Endothelial Growth Factor Receptor-1 and Receptor-2 in Angiogenesis
Shibuya, M. (2006) · BMB Reports · doi:10.5483/bmbrep.2006.39.5.469 · Cited by 623
“Interestingly, the GTP-form of Ras (active Ras) is hardly detected after the activation of VEGFR2, and dominant negative Ras mutants could not block this PKC-dependent MAP-kinase activation via VEGFR2 (Xia et al., 1996; Takahashi et al., 1999).”
BackgroundTakahashi, T., Ueno, H., & Shibuya, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202527 · Cited by 571
“In NIH3T3-KDR cells, VEGF-induced MAP kinase was mainly mediated by PKC. Recently, Xia et al. have reported that a PKCb inhibitor strongly suppressed VEGF-dependent endothelial cell growth (Xia et al., 1996).”
BackgroundResultMichell, B. J., Chen, Z.-P., Tiganis, T., Stapleton, D., Katsis, F., Power, D. A., Sim, A. T., & Kemp, B. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100122200 · Cited by 560
Fujio, Y., & Walsh, K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16349 · Cited by 553
VEGF-A splicing: the key to anti-angiogenic therapeutics?
Harper, S. J., & Bates, D. O. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2505 · Cited by 514
“VEGF-A 165 also stimulates robust phosphorylation of tyrosine 1175, resulting in activation of phospholipase Cγ, phosphoinositide 3-kinase and diacylglycerol production, and activation of the Raf–MEK–Erk pathway in a protein kinase C-dependen”
BackgroundVEGF Receptor Signal Transduction
Matsumoto, T., & Claesson-Welsh, L. (2001) · Science's STKE · doi:10.1126/stke.2001.112.re21 · Cited by 502
“VEGF-A stimulates p85 subunit tyrosine phosphorylation and increased PI3K enzymatic activity in a variety of endothelial cells (164-168)--with the exception of sinusoidal endothelial cells (170)--through VEGFR-2 (150, 168, 190).”
BackgroundInfluentialOh, H., Takagi, H., Suzuma, K., Otani, A., Matsumura, M., & Honda, Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.22.15732 · Cited by 499
Self-citationThe role of protein kinase C activation and the vascular complications of diabetes
DASEVCIMEN, N., & KING, G. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.04.016 · Cited by 494
Self-citationHe, H., Venema, V. J., Gu, X., Venema, R. C., Marrero, M. B., & Caldwell, R. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.35.25130 · Cited by 488
Hyperglycemia-induced oxidative stress in diabetic complications
King, G. L., & Loeken, M. R. (2004) · Histochemistry and Cell Biology · doi:10.1007/s00418-004-0678-9 · Cited by 488
“Excess glucose may activate protein kinase C (PKC) by several mech-anisms, including through de novo synthesis of diacylglycerol (DAG), by activation of phospholipase C, and by inhibition of DAG kinase (Xia et al. 1994, 1996; King et al. 1996).”
BackgroundSelf-citationBiology and therapeutic targeting of vascular endothelial growth factor A
Pérez-Gutiérrez, L., & Ferrara, N. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00631-w · Cited by 484
“Earlier studies reported suppression of both permeability and EC proliferation by PKCβ inhibitors 107,220 .”
BackgroundAbnormal angiogenesis in diabetes mellitus
Martin, A., Komada, M. R., & Sane, D. C. (2003) · Medicinal Research Reviews · doi:10.1002/med.10024 · Cited by 455
KOYA, D., HANEDA, M., NAKAGAWA, H., ISSHIKI, K., SATO, H., MAEDA, S., SUGIMOTO, T., YASUDA, H., KASHIWAGI, A., WAYS, D. K., et al. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.3.439 · Cited by 427
“Furthermore, a variety of glomerular and mesangial cell dysfunction caused by diabetes or high glucose was mimicked by phorbol esters, which directly activate PKC, and abrogated by PKC inhibitors, implicating PKC activation in the pathogenesis of glomerular and mesangial dysfunction in diabetes (7, 23, 24).”
BackgroundSelf-citationVascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis
Karkkainen, M. J., & Petrova, T. V. (2000) · Oncogene · doi:10.1038/sj.onc.1203855 · Cited by 427
“VEGF has been shown to selectively activate the Ca2+ - sensitive PKC isoforms g and b2 in bovine aortic endothelial cells (Xia et al., 1996; Takahashi et al., 1999) and PKCe in HUVE cells (Wu et al., 2000).”
BackgroundRegulation of vascular permeability by vascular endothelial growth factors
Bates, D. O., & Harper, S. J. (2002) · Vascular Pharmacology · doi:10.1016/s1537-1891(03)00011-9 · Cited by 411
The role of VEGF receptors in angiogenesis; complex partnerships
Cébe-Suarez, S., Zehnder-Fjällman, A., & Ballmer-Hofer, K. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5426-3 · Cited by 405
Targeting the protein kinase C family: are we there yet?
Mackay, H. J., & Twelves, C. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2168 · Cited by 373
“For example, vascular endothelial growth factor ( VEGF ) acts through VEGF receptor 2 ( VEGFR2 ; also known as kinase insert domain-containing receptor) and subsequent PLCγ tyrosine phosphorylation to promote the activation of PKCβ in endothelial cell”
BackgroundSchrijvers, B. F., De Vriese, A. S., & Flyvbjerg, A. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0018 · Cited by 353
“Furthermore, PKC , - I, - II, - , - , and - isoforms were identified by immunoblotting in vascular endothelial cells (269).”
BackgroundSlevin, M., Kumar, S., & Gaffney, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109443200 · Cited by 346
Zhou, J.-R., Gugger, E. T., Tanaka, T., Guo, Y., Blackburn, G. L., & Clinton, S. K. (1999) · The Journal of Nutrition · doi:10.1093/jn/129.9.1628 · Cited by 343
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Podar, K., & Anderson, K. C. (2005) · Blood · doi:10.1182/blood-2004-07-2909 · Cited by 343
Characterization of Human Chorionic Gonadotropin as a Novel Angiogenic Factor
Zygmunt, M., Herr, F., Keller-Schoenwetter, S., Kunzi-Rapp, K., Münstedt, K., Rao, C. V., Lang, U., & Preissner, K. T. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020642 · Cited by 342
Chou, E., Suzuma, I., Way, K. J., Opland, D., Clermont, A. C., Naruse, K., Suzuma, K., Bowling, N. L., Vlahos, C. J., Aiello, L. P., et al. (2002) · Circulation · doi:10.1161/hc0302.102143 · Cited by 337
Self-citationTumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Kevil, C. G., Payne, D. K., Mire, E., & Alexander, J. S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.24.15099 · Cited by 320
Protein kinase C and the development of diabetic vascular complications
Way, K. J., Katai, N., & King, G. L. (2001) · Diabetic Medicine · doi:10.1046/j.0742-3071.2001.00638.x · Cited by 313
Self-citationSignaling mechanisms mediating vascular protective actions of vascular endothelial growth factor
Zachary, I. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.280.6.c1375 · Cited by 301
Role of vascular endothelial growth factor in diabetic vascular complications
Aiello, L. P., & Wong, J.-S. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.07718.x · Cited by 293
Self-citationD'Andrea, L. D., Iaccarino, G., Fattorusso, R., Sorriento, D., Carannante, C., Capasso, D., Trimarco, B., & Pedone, C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505047102 · Cited by 290
Shen, B.-Q., Lee, D. Y., & Zioncheck, T. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.46.33057 · Cited by 286
Wu, L.-W., Mayo, L. D., Dunbar, J. D., Kessler, K. M., Baerwald, M. R., Jaffe, E. A., Wang, D., Warren, R. S., & Donner, D. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.7.5096 · Cited by 286
Idris, I., Gray, S., & Donnelly, R. (2001) · Diabetologia · doi:10.1007/s001250051675 · Cited by 285
Bouloumié, A. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00228-4 · Cited by 281
Signaling via Vascular Endothelial Growth Factor Receptors
Petrova, T. V., Makinen, T., & Alitalo, K. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4707 · Cited by 277
Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis
Shibuya, M. (2008) · BMB Reports · doi:10.5483/bmbrep.2008.41.4.278 · Cited by 277
“downstream c-Raf-MEK-MAP-kinase pathway towards DNA synthesis in endothelial cells (52, 53).”
BackgroundLabrecque, L., Royal, I., Surprenant, D. S., Patterson, C., Gingras, D., & Béliveau, R. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-07-0379 · Cited by 275
“The activation of VEGFR-2 induces dimerization and transphosphorylation of the receptors, followed by tyrosine phosphorylation and/or activation of several downstream substrates, including the second messenger-producing enzymes phospholipase C and phosphatidylinositol 3-kinase (Guo et al., 1995; Xia et al., 1996), p12…”
BackgroundIshii, H., Koya, D., & King, G. L. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050187 · Cited by 274
Self-citationOtani, A., Takagi, H., Suzuma, K., & Honda, Y. (1998) · Circulation Research · doi:10.1161/01.res.82.5.619 · Cited by 266
Self-citationProtein kinase C (PKC) family in cancer progression
Koivunen, J., Aaltonen, V., & Peltonen, J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.03.033 · Cited by 261
Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis.
Kimura, H., & Esumi, H. (2003) · Acta Biochimica Polonica · doi:10.18388/abp.2003_3713 · Cited by 258
“IP 3 induces the influx of calcium (Busse & Mulsch, 1990; Wu et al., 1999; Xia et al., 1996).”
BackgroundRegulation of microvascular permeability by vascular endothelial growth factors*
Bates, D. O., Hillman, N. J., Williams, B., Neal, C. R., & Pocock, T. M. (2002) · Journal of Anatomy · doi:10.1046/j.1469-7580.2002.00066.x · Cited by 258
Safi, S. Z., Qvist, R., Kumar, S., Batumalaie, K., & Ismail, I. S. B. (2014) · BioMed Research International · doi:10.1155/2014/801269 · Cited by 257
Suzuma, K., Naruse, K., Suzuma, I., Takahara, N., Ueki, K., Aiello, L. P., & King, G. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006509200 · Cited by 240
Self-citationPhosphoinositide 3-kinase signalling in the vascular system
Morello, F., Perino, A., & Hirsch, E. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn325 · Cited by 235
Minami, T., Horiuchi, K., Miura, M., Abid, M. R., Takabe, W., Noguchi, N., Kohro, T., Ge, X., Aburatani, H., Hamakubo, T., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406454200 · Cited by 232
Vascular endothelial growth factor in heart failure
Taimeh, Z., Loughran, J., Birks, E. J., & Bolli, R. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.94 · Cited by 231
Naruse, K., Rask-Madsen, C., Takahara, N., Ha, S.-W., Suzuma, K., Way, K. J., Jacobs, J. R. C., Clermont, A. C., Ueki, K., Ohshiro, Y., et al. (2006) · Diabetes · doi:10.2337/diabetes.55.03.06.db05-0771 · Cited by 220
“We have previously shown that BAECs have endogenous expression of PKC , - 1, - 2, - , - , and - (19).”
BackgroundSelf-citationThe PKC-DRS Study Group (2005) · Diabetes · doi:10.2337/diabetes.54.7.2188 · Cited by 218
The role of protein kinase C activation in diabetic nephropathy
Noh, H., & King, G. L. (2007) · Kidney International · doi:10.1038/sj.ki.5002386 · Cited by 212
Self-citationShen, B.-Q., Lee, D. Y., Gerber, H.-P., Keyt, B. A., Ferrara, N., & Zioncheck, T. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.45.29979 · Cited by 211
Armesilla, A. L., Lorenzo, E., Gómez del Arco, P., Martínez-Martínez, S., Alfranca, A., & Redondo, J. M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.2032 · Cited by 198
“In accordance with a functional activation of phospholipase Cg, VEGF has also been reported to induce turnover of inositol phosphates, diacylglycerol production, and elevation of intracellular Ca(21) concentrations (3, 45, 67).”
BackgroundABU-GHAZALEH, R., Kabir, J., Jia, H., Mel, L. O. B. O., & Zachary, I. C. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3600255 · Cited by 197
Yoshiji, H., Kuriyama, S., Ways, D. K., Yoshii, J., Miyamoto, Y., Kawata, M., Ikenaka, Y., Tsujinoue, H., Nakatani, T., Shibuya, M., et al. (1999) · PubMed · Cited by 194
Igarashi, J., Erwin, P. A., Dantas, A. P. V., Chen, H., & Michel, T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934494100 · Cited by 192
Disorders of Vascular Permeability
Park-Windhol, C., & D'Amore, P. A. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044506 · Cited by 190
Vascular permeability in ocular disease and the role of tight junctions
Erickson, K. K., Sundstrom, J. M., & Antonetti, D. A. (2007) · Angiogenesis · doi:10.1007/s10456-007-9067-z · Cited by 187
“pathway has been correlated to VEGF’s mitogenic effects in endothelial cells [123].”
BackgroundPitson, S. M., Moretti, P. A. B., Zebol, J. R., Xia, P., Gamble, J. R., Vadas, M. A., D'Andrea, R. J., & Wattenberg, B. W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006176200 · Cited by 184
Self-citationOxidative Stress and Vascular Dysfunction in the Retina: Therapeutic Strategies
Ruan, Y., Jiang, S., Musayeva, A., & Gericke, A. (2020) · Antioxidants · doi:10.3390/antiox9080761 · Cited by 183
Regulators of angiogenesis and strategies for their therapeutic manipulation
Milkiewicz, M., Ispanovic, E., Doyle, J. L., & Haas, T. L. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.10.006 · Cited by 189
Protein kinase C inhibitors as novel anticancer drugs
Jirousek, M. R., & Goekjian, P. G. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.12.2117 · Cited by 182
Self-citationVEGF induces hyperpermeability by a direct action on endothelial cells
Hippenstiel, S., Krüll, M., Ikemann, A., Risau, W., Clauss, M., & Suttorp, N. (1998) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1998.274.5.l678 · Cited by 181
Wong, C., & Jin, Z.-G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503198200 · Cited by 176
Carducci, M. A., Musib, L., Kies, M. S., Pili, R., Truong, M., Brahmer, J. R., Cole, P., Sullivan, R., Riddle, J., Schmidt, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3447 · Cited by 176
CLERMONT, A. C., AIELLO, L. P., MORI, F., AIELLO, L. M., & BURSELL, S.-E. (1997) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)70860-8 · Cited by 175
Self-citationShizukuda, Y., Tang, S., Yokota, R., & Ware, J. A. (1999) · Circulation Research · doi:10.1161/01.res.85.3.247 · Cited by 174
Vascular Endothelial Growth Factor-B in Physiology and Disease
Bry, M., Kivelä, R., Leppänen, V.-M., & Alitalo, K. (2014) · Physiological Reviews · doi:10.1152/physrev.00028.2013 · Cited by 173
Shibuya, M. (2006) · Endothelium · doi:10.1080/10623320600697955 · Cited by 171
Suzuma, K., Takahara, N., Suzuma, I., Isshiki, K., Ueki, K., Leitges, M., Aiello, L. P., & King, G. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022644499 · Cited by 170
Self-citationMoccia, F., Negri, S., Shekha, M., Faris, P., & Guerra, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163962 · Cited by 170
“Early work demonstrated that VEGF-induced increase in endothelial [Ca]i stimulates the Ca2+-dependent PKCβ2 (cPKCβ2), which in turn recruits the downstream RAF1–MEK–ERK1/2 cascade more efficiently than Ras (Figure 2) [24,232,233].”
BackgroundVascular Endothelial Growth Factor Enhances Endothelial Cell Survival and Tumor Radioresistance
Gupta, V. K., Jaskowiak, N. T., Beckett, M. A., Mauceri, H. J., Grunstein, J., Johnson, R. S., Calvin, D. A., Nodzenski, E., Pejovic, M., Kufe, D. W., et al. (2002) · The Cancer Journal · doi:10.1097/00130404-200201000-00009 · Cited by 170
Microvascular complications of diabetes
He, Z., & King, G. L. (2004) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2003.12.003 · Cited by 169
Self-citationRole for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF.
Tilton, R. G., Chang, K. C., LeJeune, W. S., STEPHAN, C. C., Brock, T. A., & Williamson (1999) · PubMed · Cited by 169
Clarkin, C., Emery, R. J., Pitsillides, A. A., & Wheeler-Jones, C. P. D. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21234 · Cited by 168
“Primary HOBs were cultured from bone segments taken during routine shoulder operations at The Hospital of St John and St Elizabeth, London, by methods previously described (Zaman et al., 1999) and patient consent was gained before each operation.”
MethodLiu, D., Jia, H., Holmes, D. I. R., Stannard, A., & Zachary, I. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000098644.03153.6f · Cited by 167
Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperpermeability
Wu, H.-L., Yuan, Y., Zawieja, D. C., Tinsley, J. H., & Granger, H. J. (1999) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1999.276.2.h535 · Cited by 167
“Indeed, other studies on bovine aortic endothelial cells (30) showed that VEGF induced a concentration- and time-dependent increase in PKC activity, and the effect was preceded by the activation of PLC-g.”
BackgroundGélinas, D. S., Bernatchez, P. N., Rollin, S., Bazan, N. G., & Sirois, M. G. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704956 · Cited by 166
Aiello, L. P., Clermont, A. C., Arora, V. M., Davis, M. D., Sheetz, M. J., & Bursell, S. (2005) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-0757 · Cited by 168
“(letters correct) Placebo ( 14 ) 59.9 (3.21) 62.5 (4.52) 2.6 (3.39) 0.269 0.843”
InfluentialSelf-citationThe Potential Role of PKC β in Diabetic Retinopathy and Macular Edema
Aiello, L. P. (2002) · Survey of Ophthalmology · doi:10.1016/s0039-6257(02)00391-0 · Cited by 165
Self-citationThe lipid phosphatase LPP3 regulates extra-embryonic vasculogenesis and axis patterning
Escalante-Alcalde, D., Hernandez, L., Le Stunff, H., Maeda, R., Lee, H.-S., Cheng, G., Sciorra, V. A., Daar, I., Spiegel, S., Morris, A. J., et al. (2003) · Development · doi:10.1242/dev.00635 · Cited by 165
“Activated PKC is required for the morphogenesis of the vasculature (Tang et al., 1997; Xia et al., 1996).”
BackgroundKorpelainen, E., Karkkainen, M. J., Gunji, Y., Vikkula, M., & Alitalo, K. K. (1999) · Oncogene · doi:10.1038/sj.onc.1202288 · Cited by 167
“…to activate MAPK, p38, the PLC-g-PKC pathway and PI3K in di erent types of endothelial cells (Guo et al., 1995; Rousseau et al., 1997; Seetharam et al., 1995; Xia et al., 1996) but as these cells express more than one VEGFR type, it is not possible to attribute the results to a particular receptor.”
Background
Metadata
- Authors
- Xia, P., Aiello, L. P., Ishii, H., Jiang, Z. Y., Park, D. J., Robinson, G. S., Takagi, H., Newsome, W. P., Jirousek, M. R., & King, G. L.
- Affiliations
- Joslin Diabetes Center (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Eli Lilly (United States) (US)
- Venue
- Journal of Clinical Investigation
- Published
- 1996-11-01
- Volume
- 98
- Issue
- 9
- Pages
- 2018-2026
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC507645
- OpenAlex
- W2075553837
- Cited by
- 566
- References
- 39
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 5 · 2021: 6 · 2020: 7 · 2019: 8 · 2018: 3 · 2017: 3 · 2016: 9 · 2015: 8 · 2014: 14 · 2013: 21 · 2012: 19
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (5r01dk036433-10, 5r29ey010827-04, 5r01ey005110-18, EY05110)
- National Eye Institute (EY10827, EY05110)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK36433)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- vascular endothelial growth factor, protein kinase C, PKC isoforms, PKC beta, endothelial cell proliferation, signal transduction, phospholipase C-gamma, phosphatidylinositol 3-kinase, diacylglycerol, ruboxistaurin, genistein, wortmannin, bovine aortic endothelial cells
- MeSH terms
- Animals, Cattle, Cell Division, Diglycerides, Endothelium, Vascular, Enzyme Activation, Inositol Phosphates, Isoenzymes, Lymphokines, Type C Phospholipases, Protein Kinase C, Signal Transduction, Endothelial Growth Factors, DNA, Antisense, Phosphotransferases (Alcohol Group Acceptor), Phosphotyrosine, Phosphatidylinositol 3-Kinases, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Phospholipase C gamma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.